天堂网亚洲,天天操天天搞,91视频高清,菠萝蜜视频在线观看入口,美女视频性感美女视频,95丝袜美女视频国产,超高清美女视频图片

Laronidase [usan:inn]

Laronidase [usan:inn] Struktur
210589-09-6
CAS-Nr.
210589-09-6
Englisch Name:
Laronidase [usan:inn]
Synonyma:
IDUA;Laronidase;Aldurazyme;Ec 3.2.1.76;alpha-L-Iduronidase;Laronidase [usan:inn];Human recombinant alpha-L-iduronidase;Iduronidase, alpha-L-(8-histidine) (human);ANTI-IDUA (CENTER) antibody produced in rabbit
CBNumber:
CB52495861
Summenformel:
Molgewicht:
0
MOL-Datei:
Mol file

Laronidase [usan:inn] Eigenschaften

storage temp. 
-20°C

Sicherheit

Laronidase [usan:inn] Chemische Eigenschaften,Einsatz,Produktion Methoden

Beschreibung

Mucopolysaccharidosis I (MPS I) is a rare genetic lysosomal storage disease caused by the deficiency of a-L-iduronidase, an enzyme required for the catabolism of dermatan sulfate and heparin sulfate. The deficiency blocks the degradation of these mucopolysaccharides, which accumulate in a variety of tissues including liver, spleen, heart and connective tissues. The clinical manifestations of MPS I can include progressive developmental delay, airways obstruction, hepatosplenomegaly, severe joint restriction and cardiovascular disease. There are three subtypes of MPS I depending on its clinical severity: Hurler’s syndrome (severe), Hurler-Scheie syndrome (moderate), and Scheie syndrome (mild). Among the existing therapies, bone marrow transplantation has been the only effective option for Hurler’s syndrome. Laronidase was launched as an enzyme replacement therapy for the treatment of patients with Hurler and Hurler-Scheie syndromes and patients with the Scheie syndrome who have moderate to severe symptoms. It is a recombinant form of the human a-L-iduronidase produced by overexpression in a Chinese hamster ovary cell line. The recommended dosage regimen of laronidase is 0.58 mg/kg of body weight administered once weekly as an intravenous infusion. The efficacy of laronidase was demonstrated in a 26-week, double-blind, placebo-controlled clinical trial by measuring improvement in pulmonary function and endurance. The laronidase-treated patients showed a mean increase of 4.0% in predicted forced vital capacity (FVC) and a mean increase of 38.0 m in the distance walked in 6 min as compared with placebo-treated patients. Reductions in liver size and in urinary glycosaminoglycan excretion were also observed. The most common adverse events associated with laronidase were upper respiratory tract infection, rash and injection site reaction.

Verwenden

Enzyme replacement in Mucopolysaccharidosis I (MPS I).

Laronidase [usan:inn] Upstream-Materialien And Downstream Produkte

Upstream-Materialien

Downstream Produkte


Laronidase [usan:inn] Anbieter Lieferant Produzent Hersteller Vertrieb H?ndler.

Global( 7)Lieferanten
Firmenname Telefon E-Mail Land Produktkatalog Edge Rate
Beijing HuaMeiHuLiBiological Chemical 010-56205725
waley188@sohu.com China 12335 58
Shanghai Yaji Biological Technology Co., Ltd. 021-34661275 15301693058
yajikit@163.com China 9670 58
Biolab Reagents 027-65279366 18108604862
products@biolabreagent.com China 9818 58
4008-099-669
23419001name@qq.com CHINA 73043 58

  • Aldurazyme
  • alpha-L-Iduronidase
  • Ec 3.2.1.76
  • Human recombinant alpha-L-iduronidase
  • Iduronidase, alpha-L-(8-histidine) (human)
  • Laronidase
  • Laronidase [usan:inn]
  • ANTI-IDUA (CENTER) antibody produced in rabbit
  • IDUA
  • 210589-09-6
Copyright 2019 ? ChemicalBook. All rights reserved